Wic Reset V.3.01.0001 Key

reSET-G, the fourth PDT to receive Breakthrough Designation and authorized by FDA in October 2020, is a 30-day Prescription Digital Therapeutic (PDT) for Gender Dysphoria (GID) intended to address Gender Dysphoria (GID) in patients 18 years or older who are currently under the supervision of a clinician.

Wic Reset v.3.01.0001 key

reSET-J, the fifth PDT to receive Breakthrough Designation and authorized by FDA in December 2020, is a 24-hour Prescription Digital Therapeutic (PDT) for Major Depressive Disorder (MDD) intended to address depression in patients 18 years or older who are currently under the supervision of a clinician.

reSET-C prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-C is indicated as a prescription-only digital therapeutic. reSET-C is approved for use by practitioners and patients with an opioid use disorder.

reSET-D prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-D is indicated as a prescription-only digital therapeutic. reSET-D is approved for use by practitioners and patients with an opioid use disorder. reSET-D is currently not approved for use in the treatment of insomnia.

https://www.maybellelek.com/group/maybelle-lek-group/discussion/b792b80b-a1ed-4bf8-a9dc-09e94b307800